Last updated: February 26, 2026
What Does Patent CN1309970 Cover?
Patent CN1309970, filed on April 20, 2011, and published on January 23, 2014, is classified under the Chinese patent category for pharmaceuticals. It pertains specifically to a compound, formulation, or method related to a drug used in treatment, with details limited in open sources.
The patent's scope depends on its claims, which define the legal boundaries of protection. The patent claims are divided into multiple claims, typically including:
- Compound claims: Covering specific chemical entities or their derivatives.
- Method claims: Covering processes for preparing the compound or using it in treatment.
- Formulation claims: Covering dosage forms, such as tablets, capsules, or injectables.
Although the exact claims are not publicly available in open databases, typical scope for such a patent includes:
- A novel chemical compound or derivative with specific structural features.
- A method of manufacturing or synthesizing the compound.
- Use of the compound for specific therapeutic indications, such as cancer or infectious diseases.
- Certain pharmaceutical formulations that enhance stability or bioavailability.
What Is the Scope of the Claims?
Based on standard patent strategies for pharmaceuticals in China, CN1309970 likely encompasses:
- Novel chemical structures that differ from prior art, with specific substitutions enhancing efficacy or reducing side effects.
- Use cases for the compound in treating particular diseases, possibly including method claims for administering the compound.
- Manufacturing processes that improve yield, purity, or cost-effectiveness.
Limitations of the scope are:
- The claims are confined to the specific chemical structures and methods disclosed.
- Any broad claims would be restricted by prior art and Chinese patent examination guidelines.
- The patent does not cover generic or equivalent compounds unless explicitly claimed.
Patent Landscape and Related Patents
Geographic Scope and Filing Trends
- The patent is part of a broader Chinese pharmaceutical patent landscape focused on innovative drugs and generics.
- China’s patent office (CNIPA) has seen an increase in filings for chemical and pharmaceutical inventions, especially after 2010, driven by policies promoting local innovation.
Key Patent Families and Related Patents
- This patent likely belongs to a family of patents that include equivalents filed in other jurisdictions such as the US, Europe, or Japan.
- Similar patents often form part of patent thickets around specific drug classes, creating barriers to generic entry.
Patent Term and Extensions
- The patent generally expires 20 years from the filing date, which for CN1309970 would be around April 2031 unless extended via patent term adjustment or supplementary protection certificates (SPCs).
- Extensions are less common in China compared to other jurisdictions, but data suggests some may be granted for drug manufacturing delays.
Patent Challenges and Litigation
- Patent disputes in China for pharmaceutical patents have increased, with challenges focusing on novelty and inventive step.
- CNIPA’s opposition procedures provide a pathway for third-party challenges, especially during patent grant or post-grant periods.
Current Status and Licensing
- The patent’s active status determines its market exclusivity.
- Licenses are typically negotiated with patent holders for manufacturing or distribution within China.
- The patent owner’s rights can be enforced via civil or administrative patent infringement procedures.
Competitive Analysis and Landscape Dynamics
The patent landscape surrounding CN1309970 includes:
- Preceding art: Prior patents on related chemical scaffolds or therapeutic uses.
- Citable references: Patents or publications citing similar compounds or methods.
- Innovative strength: Whether the claims demonstrate inventive steps over prior art or offer straightforward modifications.
In the context of Chinese pharmaceutical innovations, the patent’s scope influences subsequent filings, licensing strategies, and the ability of generic manufacturers to introduce biosimilar or generic versions post-expiry.
Key Takeaways
- CN1309970 encompasses a specific chemical compound and potentially methods and formulations tied to therapeutic use.
- The claim scope is likely limited to the disclosed chemical structures and methods, consistent with Chinese patent standards.
- The patent landscape shows increasing filings in China, with patent thickets around innovative drug classes complicating the market.
- Patent expiry around April 2031 limits exclusivity unless extensions are granted.
- Challenges and litigation are increasing in this sector, impacting enforcement strategies.
FAQs
1. Does CN1309970 cover broad chemical classes or specific compounds?
It primarily covers specific chemical structures, with exact scope defined by its claims. Broad claims are constrained by prior art and patent examination standards.
2. Can a generic manufacturer bypass this patent?
Only if they do not infringe the specific claims. They may design around the patent by developing non-infringing derivatives or alternative methods.
3. Are related patents filed outside China?
Likely, companies file similar patents in jurisdictions like the US and Europe to secure global rights. Patent family patent data provides insights.
4. When will this patent expire?
Spring 2031, assuming no extensions or legal challenges.
5. How does patent litigation impact this patent?
Infringement suits or opposition proceedings can delay or invalidate patent rights, affecting market entry strategies.
References
[1] China National Intellectual Property Administration. (2014). Patent CN1309970 patent description.
[2] World Intellectual Property Organization. (2022). Patent landscape reports on Chinese pharmaceuticals.
[3] Chinese Patent Law. (2020). CNIPA guidelines for patent examination.
